Study
|
Study arma
|
Unspecified dose adjustment (direction not specified), point estimate (%) for incidence (95% CI)
|
Dose increase, point estimate (%) for incidence (95% CI)
|
Dose decrease, point estimate (%) for incidence (95% CI)
|
---|
Allegra 2017 [48]
|
Control (N = 99)
|
72.7 (64.0, 81.5)
|
–
|
–
|
Nomogramb (N = 92)
|
60.9 (50.9, 70.8)
|
–
|
–
|
Buhler 2014 [49]
|
(N = 2074)
|
–
|
4.8 (3.9, 5.7)
|
3.7 (2.9, 4.5)
|
Magnusson 2017 [58]
|
AMH (N = 152)
|
54.6 (46.7, 62.5)
|
–
|
–
|
Non-AMH (N = 155)
|
52.3 (44.4, 60.1)
|
–
|
–
|
Espinós 2017c [52]
|
(N = 41)
|
26.8 (13.3, 40.4)
|
–
|
–
|
Nyboe Andersen 2017 [9]
|
r-hFSH (N = 661)
|
36.8 (33.1, 40.4)
|
–
|
–
|
Rettenbacher 2015 [62]
|
Bemfola (N = 220)
|
–
|
–
|
17.3 (12.3, 22.3)
|
GONAL-f (N = 113)
|
–
|
–
|
14.2 (7.7, 20.6)
|
Strowitzki 2016 [63]
|
Ovaleap (N = 153)
|
–
|
35.9 (28.3, 43.6)
|
15.0 (9.4, 20.7)
|
GONAL-f (N = 146)
|
–
|
43.2 (35.1, 51.2)
|
15.1 (9.3, 20.9)
|
Devroey 2012 [50]
|
r-hFSH (N = 375)
| |
24.8 (20.4, 29.2)
|
2.1 (0.7, 3.6)
|
Durnerin 2008 [51]
|
Control (N = 49)
|
–
|
55.1 (41.2, 69.0)
|
2.0 (−1.9, 6.0)
|
r-hLH pretreat (N = 53)
|
–
|
54.7 (41.3, 68.1)
|
3.8 (−1.4, 8.9)
|
Esteves 2009 [53]
|
r-hFSH (N = 236)
|
–
|
–
|
53.4 (47.0, 59.8)
|
Devroey 2009 [54]
|
r-hFSH (N = 750)
|
–
|
–
|
8.4 (6.4, 10.4%)
|
Freiesleben 2008 [55]
|
r-hFSH (N = 159)
|
44.0 (36.3, 51.7)
|
–
|
–
|
Kyrou 2009 [56]
|
r-hFSH (N = 230)
|
–
|
3.0 (0.8, 5.3)
|
7.0 (3.7, 10.2)
|
Lossl 2008 [57]
|
Androgen priming (N = 53)
|
–
|
58.5 (45.2, 71.8)
|
1.9 (−1.8, 5.5)
|
Control (N = 50)
|
–
|
52.0 (38.2, 65.8)
|
2.0 (−1.9, 5.9)
|
Nakhuda 2010d [59]
|
(N = 104)
|
–
|
10.6 (4.7, 16.5)
|
35.6 (26.4, 44.8)
|
Nyboe Andersen 2008 [60]
|
r-hFSH (N = 261)
|
–
|
51.7 (45.7, 57.8)
|
11.5 (7.6, 15.4)
|
r-hFSH + r-hLH (N = 265)
|
–
|
48.7 (42.7, 54.7)
|
11.3 (7.5, 15.1)
|
Requena 2010 [61]
|
r-hFSH + HP-hMG (N = 46)
|
–
|
32.6 (19.1, 46.2)
|
–
|
r-hFSH (N = 46)
|
–
|
32.6 (19.1, 46.2)
|
–
|
Yovich 2012 [40]
|
FSH dose < 100 IU (N = 47)
|
–
|
53.2 (38.9, 67.5)
|
–
|
- AMH anti-Müllerian hormone, FSH follicle stimulating hormone, r-hFSH recombinant-human follicle stimulating hormone, r-hLH recombinant-human luteinizing hormone, HP-hMG highly purified human menopausal gonadotropin
- aOnly study arms using recombinant FSH were included in the data analysis; bFSH starting dose set using a nomogram based on age, serum Day 3 FSH and AMH; cStudy in obese women; dStudy in oocyte donors